Health Condition 1: E349- Endocrine disorder, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Intervention4: Nil: Nil
Intervention5: Nil: Nil
Intervention6: Nil: Nil
Sponsors
SUHANI SHARMA
Eligibility
Inclusion criteria
Inclusion criteria: All eligible patients diagnosed with NAFLD and individuals without NAFLD were recruited consecutively and included in the study after obtaining informed consent.
Exclusion criteria
Exclusion criteria: Participants with significant alcohol intake, viral hepatitis or other chronic liver diseases, pregnancy or lactation, severe psychiatric disorders precluding questionnaire completion, inability or unwillingness to provide informed consent, and those with incomplete clinical, laboratory, or questionnaire data were excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1 Prevalence and severity of depressive symptoms in patients with NAFLD assessed using the Patient Health Questionnaire 9 score at baseline. 2 Association between hepatic steatosis and liver fibrosis severity assessed by FibroScan and systemic inflammatory indices including Neutrophil Lymphocyte Ratio. Platelet Lymphocyte Ratio, and Systemic Immune Inflammation Index, along with depression scores PHQ 9 among NAFLD patients and individuals without NAFLD at baseline. Timepoint: SINGLE TIME POINT | — |
Secondary
| Measure | Time frame |
|---|---|
| 3. Quality of life assessment in patients with NAFLD using the WHO Quality of Life BREF questionnaire at baseline. 4. Severity grading of hepatic steatosis & liver fibrosis using FibroScan & evaluation of its association with the following demographic & clinical variables at baseline 1. Age 2. Gender 3. Dietary pattern 4. Socioeconomic status, assessed using the Modified Kuppuswamy Socioeconomic Status Scale. Timepoint: SINGLE TIME POINT | — |
Countries
India
Contacts
Public ContactDr Mohd Ashif Khan
Fortis Escorts Heart Institute and Research Centre
Outcome results
None listed